Modality
Radioligand
MOA
BCMA ADC
Target
Cl18.2
Pathway
Autophagy
FL
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
~Nov 2020
→ ~Feb 2022
Phase 2
~May 2022
→ ~Aug 2023
Phase 3
~Nov 2023
→ ~Feb 2025
NDA/BLA
May 2025
→ Aug 2027
NDA/BLACurrent
NCT05804000
2,027 pts·FL
2025-12→2026-04·Recruiting
NCT08592486
556 pts·FL
2025-05→2027-08·Completed
2,583 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-243w awayPh3 Readout· FL
2027-08-161.4y awayPh3 Readout· FL
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3
NDA/BLA
Complet…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2026-04-24 · 3w away
FL
Ph3 Readout
2027-08-16 · 1.4y away
FL
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05804000 | NDA/BLA | FL | Recruiting | 2027 | 6MWD |
| NCT08592486 | NDA/BLA | FL | Completed | 556 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |